Humoral response to mRNA anti–COVID-19 vaccines BNT162b2 and mRNA-1273 inpatients with chronic lymphocytic leukemia
| Autor: | Stéphanie Malartre, Cristina Bagacean, Véronique Leblond, Aline Clavert, Hugo Legendre, Caroline Dartigeas, Nanthara Sritharan, Bernard Drenou, Kamel Laribi, Xavier Troussard, Ségolène Brichler, Anne-Sophie Michallet, Driss Chaoui, Alain Delmer, Lise Willems, Christian Puppinck, Cécile Tomowiak, Fatiha Merabet, Damien Roos-Weil, Chadi Al-Nawakil, Florence Cymbalista, Rémi Letestu, Marie C. Béné, Romain Guieze, Vincent Levy, Philippe Genet |
|---|---|
| Přispěvatelé: | Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), Université Clermont Auvergne (UCA) |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
COVID-19 Vaccines medicine.drug_class Chronic lymphocytic leukemia Monoclonal antibody Antibodies Viral Gastroenterology chemistry.chemical_compound Chemoimmunotherapy Internal medicine medicine Humans RNA Messenger Seroconversion BNT162 Vaccine Aged Response rate (survey) Messenger RNA Venetoclax business.industry SARS-CoV-2 COVID-19 [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology Hematology medicine.disease Stimulus Report Leukemia Lymphocytic Chronic B-Cell Vaccination mRNA vaccine chemistry third dose business CLL 2019-nCoV Vaccine mRNA-1273 |
| Zdroj: | Blood Advances Blood Advances, The American Society of Hematology, 2022, 6 (1), pp.207-211. ⟨10.1182/bloodadvances.2021006215⟩ |
| ISSN: | 2473-9537 2473-9529 |
| DOI: | 10.1182/bloodadvances.2021006215⟩ |
| Popis: | Immunocompromised individuals such as patients with chronic lymphocytic leukemia (CLL) are at risk of impaired immune responses to vaccination. The objective of our study was to evaluate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–specific antibody responses in patients with CLL after the first, second, and third doses of the BNT162b2 or mRNA-1273 vaccines and after a single dose for patients with confirmed previous COVID-19. In all, 530 patients were included in the study. Patients received 2 doses at a 4-week interval and a third dose if they were seronegative after the second dose. Response rate was 27% after dose 1 and 52% after dose 2. Post-dose 2 treatment-naïve patients had the highest response rate (72%) followed by patients previously treated by chemoimmunotherapy (60%). Among patients receiving therapy, those receiving Bruton tyrosine kinase inhibitor alone (22%) or in combination with anti-CD20 monoclonal antibodies or venetoclax (0%) had the poorer response rate whereas patients who received venetoclax monotherapy achieved a significantly higher response rate (52%). A multivariable analysis identified age older than 65 years, ongoing CLL treatment, and gamma globulin ≤6 g/L as independent predictors of the absence of seroconversion. Post-dose 2 seronegative patients had a global response rate of 35% after dose 3. This study provides an argument for the use of a third dose and for prophylactic SARS-CoV-2 neutralizing monoclonal antibodies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|